- South Korea
- /
- Healthtech
- /
- KOSDAQ:A328130
Three Stocks That May Be Trading Below Estimated Value In November 2024
Reviewed by Simply Wall St
As global markets navigate the uncertainties surrounding the incoming Trump administration's policies, investors are witnessing a mixed performance across various sectors and indices. Amidst this backdrop of fluctuating interest rates and sector-specific volatility, identifying stocks that may be trading below their estimated value can present intriguing opportunities for investors seeking to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows
Name | Current Price | Fair Value (Est) | Discount (Est) |
Giant Biogene Holding (SEHK:2367) | HK$48.90 | HK$97.69 | 49.9% |
Wistron (TWSE:3231) | NT$114.00 | NT$227.50 | 49.9% |
SISB (SET:SISB) | THB31.75 | THB63.41 | 49.9% |
Shoei (TSE:7839) | ¥2368.00 | ¥4720.11 | 49.8% |
A.L.A. società per azioni (BIT:ALA) | €24.80 | €49.51 | 49.9% |
EnomotoLtd (TSE:6928) | ¥1474.00 | ¥2940.30 | 49.9% |
Enento Group Oyj (HLSE:ENENTO) | €18.06 | €36.11 | 50% |
Intermedical Care and Lab Hospital (SET:IMH) | THB4.94 | THB9.87 | 50% |
Saipem (BIT:SPM) | €2.327 | €4.65 | 50% |
Credit Clear (ASX:CCR) | A$0.355 | A$0.71 | 50% |
Let's take a closer look at a couple of our picks from the screened companies.
CVC Capital Partners (ENXTAM:CVC)
Overview: CVC Capital Partners plc is a private equity and venture capital firm focusing on middle market secondaries, infrastructure and credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales, and spinouts with a market cap of €22.37 billion.
Operations: CVC Capital Partners plc operates across various investment strategies, including middle market secondaries, infrastructure and credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales, and spinouts.
Estimated Discount To Fair Value: 18.7%
CVC Capital Partners is trading at a discount, approximately €21.46 versus an estimated fair value of €26.39, suggesting it may be undervalued based on cash flows. Despite high debt levels, CVC's earnings are projected to grow significantly at 41.87% annually over the next three years, outpacing the Dutch market's growth rate and indicating strong potential for future profitability. However, revenue growth forecasts remain moderate compared to its earnings outlook.
- Upon reviewing our latest growth report, CVC Capital Partners' projected financial performance appears quite optimistic.
- Navigate through the intricacies of CVC Capital Partners with our comprehensive financial health report here.
Lunit (KOSDAQ:A328130)
Overview: Lunit Inc. develops AI-based software solutions for cancer screening, diagnosis, and treatment with a market cap of ₩1.87 billion.
Operations: Lunit Inc.'s revenue segments are focused on AI-based software solutions for cancer screening, diagnosis, and treatment.
Estimated Discount To Fair Value: 28.6%
Lunit is trading at ₩64,500, significantly below its estimated fair value of ₩90,378.62, highlighting potential undervaluation based on cash flows. The company's earnings are projected to grow rapidly at 78.19% annually. Recent strategic collaborations with AstraZeneca and VIDI Group enhance Lunit's AI solutions in digital pathology and breast cancer screening respectively, potentially boosting future revenue growth which is expected to outpace the broader Korean market significantly at 49.9% per year.
- Our expertly prepared growth report on Lunit implies its future financial outlook may be stronger than recent results.
- Unlock comprehensive insights into our analysis of Lunit stock in this financial health report.
Ningbo Deye Technology Group (SHSE:605117)
Overview: Ningbo Deye Technology Group Co., Ltd. specializes in manufacturing and selling heat exchangers, inverters, and dehumidifiers across China, the UK, the US, Germany, India, and other international markets with a market cap of CN¥60.54 billion.
Operations: The company generates revenue through the production and sales of heat exchangers, inverters, and dehumidifiers across its domestic and international markets.
Estimated Discount To Fair Value: 27.3%
Ningbo Deye Technology Group is trading at CN¥93.84, significantly below its estimated fair value of CN¥129.12, indicating potential undervaluation based on cash flows. The company's earnings are projected to grow 26.49% annually, surpassing the broader Chinese market's growth rate. Recent earnings reports show robust performance with net income reaching CN¥2.24 billion for the first nine months of 2024, up from CN¥1.57 billion a year ago, supporting its strong financial position and growth prospects.
- The growth report we've compiled suggests that Ningbo Deye Technology Group's future prospects could be on the up.
- Delve into the full analysis health report here for a deeper understanding of Ningbo Deye Technology Group.
Seize The Opportunity
- Take a closer look at our Undervalued Stocks Based On Cash Flows list of 921 companies by clicking here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A328130
Lunit
Develops and provides AI based software solutions for cancer screening/diagnosis and treatment.
High growth potential with adequate balance sheet.